Gå til innholdet
Global sound
The Bio Report

The Bio Report

Innovating ADCs with Dual Targeting and Smarter Delivery

· 30 min · Episode 189

Episodebeskrivelse

Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their effectiveness and tolerability in solid tumors can be constrained by inadequate tumor delivery, incomplete internalization, and off-target toxicity. NEOK Bio is seeking to overcome those challenges with its bispecific ADC platform that uses dual-antigen targeting, engineered antibodies, and next-generation linker technology. Mayank Gandhi, co-founder and CEO of NEOK Bio, discusses the company’s bispecific ADC platform, its two clinical programs, and its strategy to develop more selective therapies for patients with advanced solid tumors.

Nettsted: thebioreport.podbean.com

Live, siste time: 6 199 låter på 2 507 stasjoner i 112 land

Oppdag verden gjennom radioen

Flere måter å oppdage på (7)

Hørt noe fint? Lagre det, eller åpne det rett i Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
Star 104.5 - Gosford - 104.5 FM (AACFortsett å lytte